1. • Pawlyn C, Davies FE. Toward personalized treatment in multiple myeloma based on molecular characteristics. Blood. 2019;133:660–675. Accessed 5 Feb 2023. https://pubmed.ncbi.nlm.nih.gov/30587529/. These articles provide background on the disease process of multiple myeloma, including the guidelines utilized for diagnosis. They also describe recent treatment advances and the current prevalence of multiple myeloma in the population.
2. • Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: Eha-ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Accessed 5 Feb 2023. Ann Oncol. 2021;32:309–322. https://pubmed.ncbi.nlm.nih.gov/33549387/. These articles provide background on the disease process of multiple myeloma, including the guidelines utilized for diagnosis. They also describe recent treatment advances and the current prevalence of multiple myeloma in the population.
3. • Lawrence L. In Myeloma, New Drugs, Skyrocketing Price Tags. In: Ash Clinical News. 2019 Accessed 5 Feb 2023. https://ashpublications.org/ashclinicalnews/news/4501/In-Myeloma-New-Drugs-Skyrocketing-Price-Tags. Reference 3 outlines the development of multiple myeloma treatment, beginning in the 1990s and providing a timeline to the current state. It also includes an overview of the value that treatment has added to patients’ lives, including substantial increases in treatment response rates and 5-year survival rates. It describes the increasing costs of treatment, as well, stating that patients are struggling to afford the treatment options. Reference 4 discusses the current treatment regimen with preferred induction therapy in both transplant-eligible and transplant-non-eligible patients.
4. • Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97:1086–1107. Accessed 5 Feb 2023. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9387011/pdf/nihms-1824073.pdf. Reference 3 outlines the development of multiple myeloma treatment, beginning in the 1990s and providing a timeline to the current state. It also includes an overview of the value that treatment has added to patients’ lives, including substantial increases in treatment response rates and 5-year survival rates. It describes the increasing costs of treatment, as well, stating that patients are struggling to afford the treatment options. Reference 4 discusses the current treatment regimen with preferred induction therapy in both transplant-eligible and transplant-non-eligible patients.
5. •• Warren JL, Harlan LC, Stevens J, Little RF, Abel GA. Multiple myeloma treatment transformed: a population-based study of changes in initial management approaches in the United States. J Clin Oncol. 2013; 31(16):1984–1989. Assessed 25 March 2023. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661935/. For understanding the Medicare and Medicare Advantage enrollment, volume of patients insured by Medicare vs. Medicare Advantage, and cost implications to patients and the Medicare trust fund.